Cathie Wood’s Ark Invest continues to shake up its portfolio with a fresh round of trades, making significant moves in the biotech and fintech sectors. On Friday, Ark Invest actively bought shares in Beam Therapeutics Inc. (NASDAQ: BEAM) and Nu Holdings Ltd. (NYSE: NU) while offloading positions in MercadoLibre Inc. (NASDAQ: MELI) and Adaptive Biotechnologies Corp. (NASDAQ: ADPT). These trades showcase Ark’s strategic shifts in response to market dynamics.
Ark Invest Increases Stake in Beam Therapeutics (BEAM)
Ark Invest, through its ARK Genomic Revolution ETF (ARKG) and ARK Innovation ETF (ARKK), purchased a total of 24,640 shares of Beam Therapeutics. This follows a prior acquisition of BEAM shares just a week earlier, reinforcing Ark’s bullish stance on the biotech company.
With Beam Therapeutics closing significantly lower at -8.18% on the day, the estimated value of this purchase was close to $750,000. The company focuses on innovative gene-editing technology, which aligns with Ark’s long-term investment strategy in the healthcare sector.
Ark Invest’s Big Bet on Nu Holdings (NU)
Ark Invest also expanded its position in Nu Holdings Ltd., a leading Latin American fintech company. Through its ARK Fintech Innovation ETF (ARKF), the firm acquired 162,143 shares, amounting to over $1.75 million based on the latest closing price.
Despite a -18.0% drop, Ark’s confidence in Nu Holdings signals a strong belief in the company’s potential to disrupt traditional banking in emerging markets. The firm continues to emphasize fintech as a key driver of financial transformation.
Ark Invest Trims Holdings in MercadoLibre (MELI) and Adaptive Biotechnologies (ADPT)
While adding to its biotech and fintech positions, Ark Invest reduced its exposure to MercadoLibre Inc., Latin America’s largest e-commerce platform, and Adaptive Biotechnologies Corp., a genomics-based biotech firm.
Through ARK Fintech Innovation ETF (ARKF), Ark sold 347 shares of MercadoLibre, despite the stock gaining +6.18% on the day. Meanwhile, the firm also offloaded 8,129 shares of Adaptive Biotechnologies through ARK Genomic Revolution ETF (ARKG), even as ADPT stock closed slightly up by +0.24%.
Ark Invest’s Strategic Portfolio Adjustments
These trades highlight Ark Invest’s continued tactical reallocation across its thematic ETFs. The firm remains committed to high-growth innovation, balancing positions in emerging technology, healthcare, and fintech sectors.
With frequent shifts in its portfolio, Cathie Wood’s Ark Invest remains one of the most closely watched investment firms on Wall Street. Investors are keenly observing these strategic moves as they navigate volatile market conditions and emerging opportunities.
